The renin-angiotensin aldosterone hormonal cascade that regulates blood pressure and water (fluid) balance begins with the biosynthesis of renin by the juxtaglomerular cells that line the afferent (and occasionally efferent) arteriole of the renal glomerulus.1,2 A drop in blood pressure decreases the perfusion of the juxtaglomerular apparatus, resulting in the release of the enzyme renin. Renin proceeds to cleave angiotensinogen to produce angiotensin I. Angiotensin I is in turn converted to angiotensin II by angiotensin-converting enzyme (ACE), which is found mainly in lung capillaries. Angiotensin II is the major bioactive product of the renin-angiotensin system, binding to receptors on intraglomerular mesangial cells, causing these cells to contract along with the blood vessels surrounding them and causing the release of aldosterone from the adrenal cortex. Angiotensin II has multifaceted effects on aldosterone secretion, vasoconstriction, sodium reabsorption, and fluid volume, all of which serve to raise blood pressure. Laboratory studies with cultured cardiomyocytes have implicated angiotensin as a direct cause of left ventricular hypertrophy associated with hypertension. Angiotensin II also inhibits renin release by the kidney via a feedback mechanism.
Several investigators have found that a subgroup of patients with severe chronic heart failure has elevated plasma angiotensin II levels despite long-term ACE inhibitor use.3,4 This phenomenon has been referred to as ACE escape or angiotensin II reactivation and has been associated with increased mortality.4-7
Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.
1. Atlas SA. The renin-angiotensin system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007; 13(8 Suppl B):9-20. PubMed 17970613
2. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension. 2007; 49(6):1196-1201. PubMed 17452509
3. Roig E, Pérez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000; 21(1):53-57. PubMed 10610744
4. van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006; 106(3):367-372. PubMed 16337046
5. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999; 82(1):57-61. PubMed 10377310
6. Athyros VG, Mikhailidis DP, Kakafika AI, et al. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockage: is oral renin inhibition the solution? Expert Opin Pharmocother. 2007 Apr; 8(5):529-535. PubMed 17376010
7. Chinnaiyan KM, Alexander D, McCullough PA. Role of angiotensin II in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich). 2005; 7(12)740-747. PubMed 16330897